In vivo studies in dogs demonstrated the antiemetic efficacy of maropitant against central and peripheral emetics including apomorphine, cisplatin and syrup of ipecac. Additionally, leukopenia characterized by a neutropenia and a trend toward decreasing plasma phosphorus values was seen. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. We comply with the HONcode standard for trustworthy health information -, Warnings and cautions for Cerenia Tablets, Direction and dosage information for Cerenia Tablets. Drugs. Data sources include IBM Watson Micromedex (updated 2 Nov 2020), Cerner Multum™ (updated 2 Nov 2020), ASHP (updated 23 Oct 2020) and others. Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more. In a study of 275 canine patients presented to veterinary hospitals with a history of acute vomiting, dogs were initially administered Cerenia Injectable Solution or placebo on Day 0. Veterinarians generally prescribe Cerenia for cats in a dosage of 1 mg per kilogram of the cat’s body weight, or about 0.45 to 0.5 mg per pound, administered once every 24 hours. The absolute bioavailability of maropitant was low (24%) following oral administration of 2 mg/kg maropitant. Anorexia and weight loss may occur. If you notice any serious effects or other effects not mentioned in the package insert, please inform your veterinarian.

Possible Side Effects. Every effort has been made to ensure the accuracy of the Cerenia Tablets information published above. Available for Android and iOS devices. The exposure of 10 week old puppies to maropitant was lower than that observed in adult dogs, particularly after repeat doses of 1 or 2 mg/kg. Administer CERENIA tablets in dogs 4 months and older orally at 8 mg/kg BW.

Plasma protein binding of maropitant was high (99.5%). Cerenia Tablets may be used interchangeably with Cerenia Injectable Solution for once daily dosing for the prevention of acute vomiting. In puppies younger than 11 weeks of age, histological evidence of bone marrow hypoplasia was seen at higher frequency and greater severity in puppies treated with Cerenia than in control puppies. Following administration of apomorphine, emesis was observed in 33% (4 of 12) of dogs treated with CERENIA tablets and 100% (12 of 12) of dogs treated with placebo tablets. The probability that a dog in this study, prone to motion sickness would NOT vomit during a journey if treated with CERENIA tablets was 93%, while the probability was 48% if treated with placebo. In those field studies of veterinary patients, CERENIA tablets and injection were well tolerated in dogs presenting with various conditions. ● Hypoproteinemic dogs being treated with maropitant should be monitored closely; if adverse effects are seen, treatment should be discontinued. One female in the 20 mg/kg/day group had increased cellularity of the bone marrow.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth. For a copy of the Material Safety Data Sheet (MSDS) or to report adverse reactions call Pfizer Animal Health at 1-800-366-5288. The probability that a dog in this study, prone to motion sickness would NOT vomit during a journey if treated with CERENIA Tablets was 93%, while the probability was 48% if treated with placebo. Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Dosage and Administration. The following adverse reactions were reported during a European field study for the prevention of vomiting due to motion sickness in dogs treated with CERENIA Tablets at a minimum of 8 mg/kg orally once daily for 2 consecutive days. In laboratory model studies, CERENIA Tablets dosed at a minimum of 2 mg/kg BW reduced the number of emetic events associated with established neural (central) and humoral (peripheral) stimuli. The following adverse reactions were reported during US studies for the prevention of vomiting due to motion sickness in dogs treated with CERENIA Tablets at a minimum of 8 mg/kg orally one time. CAUTION: Federal (USA) law restricts this drug to use Number of Dogs with Emesis Due to Various Clinical Conditions Treated in U.S. Clinical Veterinary Patient Study with CERENIA tablets and injection. Available for Android and iOS devices. Dogs should be fed 1 hour before treatment with CERENIA tablets and CERENIA tablets should be administered 2 hours prior to the car ride. At 8 mg/kg dose: Feeding dogs a small amount of food one hour prior to the administration of 8 mg/kg of CERENIA tablets may mitigate vomiting that may occur within two hours post-dosing and prior to travel. by or on the order of a licensed veterinarian. Greater than dose-proportional drug exposure can be expected with an increase in dose (1-16 mg/kg PO). Decreases in reticulocyte counts were also seen in 4 (of 8) placebo treated dogs (SC saline for 5 days). Based on in vitro enzyme kinetics data, it is believed that the non-linear kinetics may be partially associated with saturation of the low capacity enzyme (CYP2D15). Substance P is found in significant concentrations in the nuclei comprising the emetic center and is considered the key neurotransmitter involved in emesis.1 By inhibiting the binding of substance P within the emetic center, maropitant provides broad-spectrum effectiveness against neural (central) and humoral (peripheral) causes of vomiting. Following administration of syrup of ipecac emesis was observed in 33% (4 of 12) of dogs treated with CERENIA tablets and in 83% (10 of 12) of dogs treated with placebo tablets. Select one or more newsletters to continue. Other clinical signs were reported in less than 0.5% of dogs. Target Animal Safety Study for Acute Vomiting. Of the 252 dogs included in the analysis for effectiveness, 32 of 64 dogs (50%) in the placebo group displayed vomiting at some time during the study and 41 of 188 dogs (21.8%) in the treated group displayed vomiting during the study period. At 24 mg/kg, CERENIA tablets caused statistically significant decreases in food consumption, with decreases in body weight, liver and testis weight; and an increase in RBC count indicating hemoconcentration, but the effects on feed consumption, body weight, and RBCs did not persist in the post-treatment recovery period (beyond Day 5). Administering CERENIA on a completely empty stomach may cause your dog to vomit. The empirical formula is C32H40N20 C6H8O7 H2O and the molecular weight 678.81. Urinary recovery of maropitant and its major metabolite was minimal (<1% each). Data sources include IBM Watson Micromedex (updated 2 Nov 2020), Cerner Multum™ (updated 2 Nov 2020), ASHP (updated 23 Oct 2020) and others. CERENIA ® (maropitant citrate), the first and only FDA‑approved veterinary antiemetic, effectively treats or prevents canine and feline vomiting from multiple causes. The chemical structure of maropitant citrate is: There were 8 dogs (4 males and 4 females) in the 2 mg/kg group and 16 dogs (8 males and 8 females) in all other groups. Dogs allocated to the placebo group were treated using either an injectable placebo solution or placebo tablets once daily at the discretion of the clinician.

Additionally, some dogs in the study tested positive for canine parvovirus, however, clinical parvoviral disease was not definitively diagnosed. For the symptomatic treatment of acute vomiting: ● In dogs 10 weeks to 7 months of age: Administer CERENIA tablets orally at 2 mg/kg body weight (BW) once daily for up to 5 consecutive days. Subscribe to Drugs.com newsletters for the latest medication news, alerts, new drug approvals and more. ● In dogs 7 months of age and older: Administer CERENIA tablets orally at 2 mg/kg body weight (BW) once daily until resolution of acute vomiting (see CAUTIONS section). At 24 mg/kg, CERENIA Tablets caused decreases in food consumption, with decreases in body weight, liver and testis weight; and an increase in RBC count indicating hemoconcentration, but the effects on feed consumption, body weight, and RBCs did not persist in the post-treatment recovery period (beyond Day 5). Hypocellular femoral bone marrow described as “minimal” was seen in 1 male that received 1 mg/kg maropitant SC for 5 days; reticulocyte counts were not available for this dog. The observed drug accumulation ratios were 2.46 and 4.81, after oral administration of 2 and 8 mg/kg, respectively. Product Description Cerenia (maropitant citrate) is the first and only FDA-approved veterinary medication to safely and effectively treat vomiting in dogs and cats and prevent vomiting due to motion sickness in dogs. Other clinical signs were reported but were <0.5% of dogs. [Review] [60 refs].

Mean (±SD) Plasma Pharmacokinetic Parameters for Maropitant in Beagle Dogs after single dose and repeat oral doses of Maropitant. Substance P is a neuropeptide of the tachykinin family found in significant concentrations in these nuclei and is considered the key neurotransmitter involved in emesis. Select one or more newsletters to continue.

CERENIA Tablets administered at 20 and 30 mg/kg caused occasional vomiting. Their vomiting status was unknown. Administer Cerenia Tablets 2 hours prior to travel. Each peach-colored oval tablet is scored and contains 16, 24, 60 or 160 mg of maropitant as maropitant citrate per tablet. Mild pain associated with injection was noted in more dogs and lasted longer in dogs that received maropitant injections compared to saline. Although hepatic first-pass metabolism contributed to the relatively low bioavailability after an oral dose, prandial status does not significantly affect the extent of oral bioavailability. Administer Cerenia Tablets orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily for up to 2 consecutive days. Maropitant produced sporadic clinical signs (salivation, emesis), body weight loss, and lower serum albumin levels at 20 mg/kg/day. Based upon in vitro enzyme kinetics, involvement of a high capacity enzyme (CYP3A12) may contribute to this return to dose linearity. Body weight and food consumption were variable throughout the 4 week acclimation period. Males administered CERENIA at 8 mg/kg orally for 2 days had a decrease in food consumption. Dogs used in the study were weaned early, minimally acclimated to the test facility, and many of the dogs in the study tested positive for coccidia. Additionally, leukopenia characterized by a neutropenia and a trend toward decreasing plasma phosphorus values was seen. To report suspected adverse events, for technical assistance or to obtain a copy of the SDS, contact Zoetis Inc. at 1-888-963-8471 or www.zoetis.com. Commonly used protein bound drugs include NSAIDs, cardiac, anticonvulsant, and behavioral medications. There were 16 dogs (8 males and 8 females) in the 0 and 24 mg/kg groups and 8 dogs (4 males and 4 females) in the 8 mg/kg group. CERENIA was used in dogs receiving other frequently used veterinary products such as fluid and electrolyte replacement solutions, antimicrobial agents, vaccines, antacids, and antiparasitic agents. Use with caution in dogs with hepatic dysfunction. Based upon in vitro enzyme kinetics, involvement of a high capacity enzyme (CYP3A12) may contribute to this return to dose linearity. Males administered CERENIA at 8 mg/kg orally for 2 days had a decrease in food consumption. The following adverse reactions were reported during a European field study for the prevention of vomiting due to motion sickness in dogs treated with Cerenia Tablets at a minimum of 8 mg/kg orally once daily for 2 consecutive days. Cerenia Tablets should be stored at controlled room temperature 20°–25°C (68°–77°F) with excursions between 15°–30°C (59°–86°F).